Indian pharmaceutical company Bharat Biotech launches oral cholera vaccine HILLCHOL (BBV131) to address global cholera challenge, targeting regions with poor sanitation.

Bharat Biotech, an Indian pharmaceutical company, has launched HILLCHOL (BBV131), a new oral cholera vaccine, to address the global cholera challenge, particularly in regions with poor sanitation. The vaccine, suitable for individuals aged over one year, was developed under a license from Hilleman Laboratories and requires administration on day 0 and day 14. With production capacity at 200 million doses, Bharat Biotech aims to help bridge the global gap in cholera vaccine supply and contribute to the Global Task Force on Cholera Control's goal of reducing cholera-related deaths by 90% by 2030.

August 27, 2024
138 Articles